EMBC

Embecta Corp
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$288.96M
P/E Ratio
3.47
EPS
$1.47
Beta
0.79
52W High
$15.08
52W Low
$2.76
50-Day MA
$3.50
200-Day MA
$8.35
Dividend Yield
9.00%
Profit Margin
8.59%
Forward P/E
PEG Ratio

About Embecta Corp

Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)$1.02B
Gross Profit (TTM)$595.10M
EBITDA$281.50M
Operating Margin23.70%
Return on Equity0.00%
Return on Assets12.20%
Revenue/Share (TTM)$17.33
Book Value$-10.81
Price-to-Book2.61
Price-to-Sales (TTM)0.28
EV/Revenue1.532
EV/EBITDA5.87
Quarterly Earnings Growth (YoY)-53.70%
Quarterly Revenue Growth (YoY)-8.10%
Shares Outstanding$56.66M
Float$54.72M
% Insiders2.02%
% Institutions91.93%

Historical Volatility

HV 10-Day
141.12%
HV 20-Day
103.21%
HV 30-Day
90.47%
HV 60-Day
75.59%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($4.00 target)
3
Hold
1
Strong Sell

Latest News

EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Newsfile Corp8/18/2026Neutral
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP  announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

PRNewsWire8/18/2026Neutral
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

NEW YORK--(BUSINESS WIRE)---- $EMBC #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.

Business Wire8/17/2026Neutral
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. So what: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire8/17/2026Neutral
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).

GlobeNewsWire8/17/2026Neutral
EMBC Court News: Embecta Securities Fraud Class Action Filed After Insulin Pen Issues and 57% Stock Drop – Contact BFA Law Before August 17

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.

GlobeNewsWire8/17/2026Neutral
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 17, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire8/17/2026Neutral
Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC

LOS ANGELES, Aug. 17, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire8/17/2026Neutral
EMBC DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – EMBC

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 17, 2026 lead plaintiff deadline.

GlobeNewsWire8/16/2026Neutral
EMBC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Embecta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Embecta between November 25, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp8/16/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EMBC and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026